|
|
||||||||
1 From the Neurologic Sciences Institute, Oregon Health and Science University, Portland.
| Abstract |
|---|
|
|
|---|
METHODS. EAE/AU was induced in Lewis rats with myelin basic protein in complete
Freunds adjuvant (CFA). The rats were scored for the development of
clinical EAE and AU. The expression of CCL5/regulated on
activation normal T-cell expressed and secreted (RANTES), CCL2/monocyte
chemotactic protein (MCP)-1, CCL3/macrophage inflammatory protein
(MIP)-1
, and CCL4/MIP-1ß and their receptors was examined at the
preclinical stage, onset, peak, and recovery by RT-PCR and ELISA.
EAE/AU rats were treated with neutralizing polyclonal antibodies
against CCL3/MIP-1
, CCL4/MIP-1ß, CCL2/MCP-1, and CCL5/RANTES and
tested for the suppression of onset of clinical AU and EAE. The control
group received normal rabbit IgG at the same dose.
RESULTS. The gene expression of those chemokines was upregulated concurrently
with symptom onset of EAE/AU and correlated with the intensity of
inflammatory changes in the eye and central nervous system (CNS). The
highest expression of CCL4/RANTES, CCL2/MCP-1, and CCL3/MIP-1
in the
eye was detected at onset of clinical uveitis, whereas CCL4/MIP-1ß
was elevated at the peak of AU. The expression of chemokine receptors
associated with T-helper (Th)1-type response, CCR1 and CCR5, correlated
with their appropriate ligands and was the highest at the peak of AU,
whereas CCR2, the receptor for CCL2/MCP-1, was present before the onset
of the disease. Treatment of anti-MIP-1ß and anti-MCP-1 significantly
delayed the onset and shortened the duration of AU and EAE.
Anti-MIP-1
treatment had no effect on clinical EAE but inhibited the
clinical signs of AU. Although CCL5/RANTES expression was observed
during the entire course of the disease, anti-RANTES treatment had no
effect on clinical disease progression.
CONCLUSIONS. The data suggest that CCL2/MCP-1, CCL3/MIP-1
, and CCL4/MIP-ß
contribute to the recruitment of inflammatory cells into the eye and
CNS and to disease activity.
| Introduction |
|---|
|
|
|---|
Chemokines are divided into two major subfamilies based on the spacing
of the first pair of N-terminal cysteine residues. This molecular
subdivision generally correlates with function. The CXC chemokines
usually recruit neutrophils, whereas CC chemokines tend to attract
monocytes. The CC chemokines are involved in the pathogenesis of
immune-mediated inflammation through monocyte-macrophage activation and
recruitment.2
3
The CC chemokines, such as CCL3/macrophage
inflammatory protein (MIP)-1
, CCL4/MIP-1ß, and CCL5/regulated on
activation normal T-cell expressed and secreted (RANTES), are efficient
chemoattractants for Th1 but not for Th2.4
CCL5/RANTES, a
chemoattractant for macrophages and mast cells, also attracts memory T
cells and NK cells.5
Another CC chemokine, CCL2/monocyte
chemotactic protein (MCP)-1, has an effect on both Th1 and Th2 cells.
The receptors for chemokines also comprise two major groups: CC
receptors (CCR), which bind CC chemokines, and CXC receptors (CXCR),
which bind CXC chemokines.6
Studies of human uveitis have shown that CXCL8/IL-8, CXCL10/IP-10
(interferon
-inducible protein-10), CCL2/MCP-1, CCL5/RANTES,
and CCL4/MIP-1ß are significantly increased during the active stages
of AU and correlate with the clinical severity of disease.
These chemokines probably play a critical role in leukocyte recruitment
in acute AU7
; however, the mechanism by which these cells
traffic to the eye and accumulate before and during clinical disease is
not well understood. It is a multistep process that includes entry of
activated T cells from peripheral lymphoid organs into the eye,
recognition of endogenous antigen in the eye, chemotactic-induced
recruitment of lymphocytes into the tissue, and disease
phase.8
9
10
11
T cell ability to secrete chemokines induces
the accumulation of other mononuclear cells and nonspecific T cells in
the perivascular space. The chemokines produced at the sites of
inflammation are likely to play a major role in the recruitment of
particular cell types that infiltrate and participate in the pathologic
lesions. They are also important for the selective migration of
particular T-cell subsets.12
Moreover, chemokines produced
by other cells including tissue-resident cells can regulate the
movement of T lymphocytes. Therefore, the relation between the
development of disease and chemokine production is important in the
pathogenic process.
To investigate the involvement of chemokines in eye inflammation, we
used the rat experimental autoimmune encephalomyelitis (EAE) model.
Rats injected with myelin basic protein (MBP) showed development of EAE
and AU.13
14
The target autoantigens in EAE and possibly
in AU include myelinated neurons found within the central nervous
system (CNS) and the iris, respectively. CD4+ T
cells of Th1 phenotype (IL-2 and IFN-
-producers) mediate EAE as well
as AU in response to encephalitogenic-uveitogenic peptides. Those
MBP-specific T cells are needed to initiate the induction of uveitis,
followed by the recruitment of polymorphonuclear leukocytes and
mononuclear leukocytes.13
15
T cells found in the
iris-ciliary body during the acute phase share characteristics with the
T cells from the spinal cord.13
16
Previously, we have shown that CCL2/MCP-1 contributes to the initial
recruitment of inflammatory cells to the eye and CNS.16
The CCL2/MCP-1 expression was detected at the preclinical phase in the
iris-ciliary body and lumbar spinal cord and increased during the
course of EAE/AU. Mononuclear infiltrating cells, endothelial cells,
and astrocytes of the CNS were identified as a source of CCL2/MCP-1 by
in situ hybridization. Kinetics of expression of Th1-type cytokines,
IL-2 and IFN-
, was in agreement with the expression of
CCL2/MCP-1.16
In view of the fact that CC chemokines have
a potential to influence the migration of T cells and monocytes across
the bloodocular barrier during inflammation and that they accumulate
in the eye, we examined the role CCL5/RANTES, CCL2/MCP-1,
CCL3/MIP-1
, and CCL4/MIP-1ß, members of the CC superfamily of
chemokines, in the pathogenesis of MBP-induced AU in Lewis rats. In the
present studies, we investigated the expression of those chemokines in
the iris-ciliary body and spinal cord of the rat with actively induced
EAE/AU. We also assessed the potential role of those chemokines in
clinical disease development by application of anti-chemokine
antibodies.
| Materials and Methods |
|---|
|
|
|---|
Induction and Assessment of AU and EAE
EAE was induced by subcutaneous injection of 25 µg guinea pig
myelin basic protein (MBP) in complete Freunds adjuvant (CFA)
supplemented with 150 µg Mycobacterium tuberculosis strain
H37Ra (Difco, Detroit, MI). The rats were assessed daily for changes in
clinical signs according to the following clinical rating scale: 0, no
signs; 1, limp tail; 2, hind leg weakness and ataxia; 3, paraplegia;
and 4, paraplegia with forelimb weakness and moribund condition. Rats
were also scored for clinical signs of ocular inflammation by
biomicroscopy according to the following scale: 0, normal; 1, slight
iris vessel dilation and thickened iris stroma, a few scattered
inflammatory cells, or both; 2, engorged blood vessels in the iris,
abnormal pupil contraction, and occasional vitreous cells; 3, hazy
anterior chamber, and decreased red reflex; and 4, marked vitreous
cells.
Preparation of RNA and cDNA
The iris-ciliary tissue was dissected from diseased and normal
eyes at various times during the course of EAE/AU, along with the
lumbar section of the spinal cord. Tissues were stored at -80°C
before RNA extraction. Total RNA was extracted from both tissues with
an extraction reagent (TRIzol; Life Technologies, Gaithersburg, MD).
All RNA preparations were treated with RNAase-free DNase. RNA
concentration was determined by spectrophotometry. First-strand cDNA
was prepared from 5 µg total RNA, each sample was annealed for 5
minutes at 65°C with 300 ng oligo(dT)12-18 and
reverse transcribed to cDNA using 80 U Moloney murine leukemia virus
reverse transcriptase (MMLV-RT) per 50 µl reaction for 1 hour at
37°C. The reaction was stopped by heating the sample for 5 minutes at
90°C.
Chemokine Expression by Touchdown RT-PCR
PCR was performed on the resultant cDNA from each sample
with specific primers for rat cytokines, chemokines, and
GAPDH (Table 1) . The amplification was performed with a thermocycler (Ericomp
Inc., San Diego, CA). The 25-µl reaction mixture consisted of 2.5
µl cDNA, 0.3 µM of sense and antisense primers, 200 µM of each
deoxynucleotide, 1.3 U Taq polymerase, 1.5 mM
MgCl2, and 1x Taq polymerase buffer.
Conditions for cytokine amplification were as follows: denaturation 1
minute at 94°C and elongation 3 minutes at 72°C. The annealing
temperatures for cytokines and chemokines were as follows: from 62°C
to 42°C was designed for MCP-1, RANTES, MIP-1ß IL-10, and IFN-
,
declining at 1°C increments and followed by 20 cycles at 50°C. The
annealing temperature for IL-2, IL-10, CCR2, and IL-4 was from 67°C
to 50°C, declining at 1°C increments and followed by 21 cycles at
55°C. The annealing temperature for MIP-1
, CCR1, CCR2, CCR3, and
CCR5 was from 67°C to 50°C, declining at 1°C increments followed
by 21 cycles at 60°C. At the end of amplification, the reaction
mixture was heated for 10 minutes at 72°C and then cooled to 4°C. A
10-µl sample of each PCR product was separated by gel electrophoresis
on 2% agarose containing ethidium bromide and then analyzed under UV
light against the DNA molecular markers. Ethidium bromidestained
bands were photographed by a digital camera for densitometry (Digital
1D Science; Eastman Kodak, Rochester, NY). The sum of intensity and
band area was determined for each PCR product and the housekeeping gene
GAPDH.
|
, the ELISA kit for
mouse MIP-1
(R&D Systems, Minneapolis, MN) was used. The standard
curve was prepared using a rat MIP-1
recombinant protein (PeproTech,
Inc., Rocky Hill, NJ).17
Isolation of Iris Cells
Cells infiltrating the iris and ciliary body were prepared from
eyes isolated from MBP-injected rats. The eyes were removed and the
iris-ciliary tissue was microdissected and placed in RPMI medium
containing 10% fetal bovine serum and 1 mg/ml collagenase for 2 hours.
A single-cell suspension was prepared by pipetting and filtering
through a cell strainer. Red blood cells were lysed, washed three
times, counted, and frozen for RNA isolation. Spinal cord mononuclear
cells were prepared and purified on a density gradient (Percoll;
Pharmacia-Upjohn, Uppsala, Sweden), according to Cohen et
al.18
Treatment of EAE/AU with Anti-chemokine Antibodies
Lewis rats were divided into five groups. Each group of four
rats received five doses of 100 µg rabbit polyclonal neutralizing
antibodies against the following chemokines: MCP-1, RANTES, MIP-1
,
and MIP-1ß (Torrey Pines Biolabs, Inc., San Diego, CA). The
antibodies were administered on days 0, 3, 6, 9, and 12 after injection
with MBP and CFA. The control group was untreated or received normal
rabbit IgG at the same dose and times. The experiment was repeated
three times. On day 18, peak of AU, rats were killed, and the eyes and
spinal cords were collected for chemokine assessment by RT-PCR.
| Results |
|---|
|
|
|---|
, CCL4/MIP-1ß, and CCL2/MCP-1, was examined. Our initial
goal was to determine whether the eye inflammation correlates with the
presence of chemokines in the eye. To determine the overall chemokine
expression during the course of ocular disease, the iris-ciliary body
tissues and spinal cord were collected at the preclinical stage (day
6), onset (day 11), AU peak (day 18), and full recovery (day 35).
Clinical assessments of EAE and AU were performed over a 40-day period.
On each day of the study three to five rats were used. The total level
of chemokine expression was determined by RT-PCR, using iris-ciliary
body or spinal cord RNA. For controls, the tissues from naïve
Lewis rats were obtained to determine the background expression for
each chemokine tested.
Chemokine mRNA expression was increased in rats with EAE/AU and
correlated with clinical ocular and neurologic symptoms in comparison
with untreated control animals, but each represented a unique pattern.
Densitometry was used to measure the products of PCR from normal rat
eyes relative to that of GAPDH (Fig. 1) . All chemokine transcripts were detected at the preclinical phase
before the onset of clinical signs. Therefore, they seem to be
important in the recruitment of cells to the eye. The expression of
CCL2/MCP-1 and CCL5/RANTES was more abundant at the mRNA level than
CCL3/MIP-1
and CCL4/MIP-1ß in both organs, although there were
differences in the transcript expression for CCL3/MIP-1
and
CCL4/MIP-1ß. CCL3/MIP-1
was expressed at the highest level before
onset of clinical signs of AU, whereas CCL4/MIP-1ß transcript was the
highest at the peak of AU. No chemokine expression was detected in
tissues without inflammation, suggesting that the cells migrate to the
eye and secrete chemokines, which subsequently amplifies the
inflammatory process.
|
CCL5/RANTES, CCL2/MIP-1
, and CCL2/MCP-1 Protein Levels in the
Eye
To determine whether mRNA expression correlates with the
production of chemokine proteins we used ELISA to assay CCL5/RANTES,
CCL3/MIP-1
, and CCL2/MCP-1 during the course of the ocular disease.
Extracts from whole eyes and spinal cords were used. After the
immunization, typical signs of EAE/AU developed in the rats (Fig. 2)
. The increase in CCL5/RANTES and CCL2/MCP-1 was observed before onset
of clinical signs in both organs. The levels of CCL2/MCP-1 and
CCL5/RANTES remained elevated through recovery in the eye. Moreover,
the protein level in the eye correlated with the expression of mRNA
(Fig. 1) . In contrast, the level of CCL5/RANTES and CCL2/MCP-1 in the
spinal cord decreased significantly to the background level after the
clinical EAE subsided. In the case of CCL3/MIP-1
, we measured only
small amounts, 20 pg per organ, at the onset of EAE and AU. This low
measured level of MIP-1
was most likely due to the low sensitivity
of the assay, rather than to the amounts of MIP-1
produced.
|
, and CCL4/MIP-1ß, were
significantly upregulated and maximized at the peak of AU, suggesting
the amplification of the Th1 response. CCR2, the major receptor for
CCL2/MCP-1, was detected at onset. In the spinal cord, all receptors
showed a trend to peak at the height of EAE and were downregulated with
recovery. In general, the expression of receptors correlated with the
appropriate chemokines; however, the expression of CCR1 and -5 was far
more abundant than CCR2 and -4 at the mRNA level in the iris-ciliary
body.
|
, as well as CCL5/RANTES,
CCL3/MIP-1
, CCL4/MIP-1ß, and CCL2/MCP-1, was detected (Fig. 4)
. No IL-4 was detected in contrast to the cells from the spinal cord,
where the message for IL-4 was detected. All receptors were expressed
on the infiltrating cells from the eye and CNS (Fig. 4)
. The transcript
CCL2/MCP-1 receptor, CCR2, was present in the eye and spinal cord over
the course of EAE/AU.
|
, CCL4/MIP-1ß, CCL2/MCP-1, and
CCL5/RANTES on days 0, 3, 6, 9, and 12. The control group received
normal rabbit IgG at the same dose. A positive control group remained
untreated. The rats were scored for the development of EAE and AU for
18 days after MBP immunization. The summary of results is presented in
Table 2
. MBP-immunized animals, which were treated with control antibodies or
were not treated in any way, had a high cumulative score, indicating
that they developed AU and EAE. Anti-RANTES had no significant effect
on amelioration of EAE and AU symptoms. Anti-MIP-1
treatment had no
effect on clinical EAE but inhibited the clinical signs of AU. Rats
developed AU, but the mean disease severity was always lower than in
control animals at the same time point. Anti-MCP-1 antibody treatment
delayed the onset by 2 days with lower severity (average AU score,
1.1) untreated control animals, suggesting its role in the
recruitment of cells to the eye. Similarly, anti-MCP-1 influenced the
onset and severity of EAE. We used antibodies from two different
commercial sources with the same effect. The most striking effect on
EAE and AU was the treatment with anti-MIP-1ß antibody. The
protection from AU and EAE lasted as long as antibodies were
administered. Two to 3 days after the last injection, EAE/AU developed.
Nonetheless, treatment of anti-MIP-1ß delayed onset and shortened the
duration of disease to 7 days (compared with 15 days in untreated
rats), but it did not dramatically suppress clinical signs of AU. This
treatment also produced a significant change in the course of EAE.
|
, IL-10, and TNF-
) in the
iris-ciliary body (Fig. 5A)
and MIP-1ß in both target organs (Fig. 5B) . Treatment with
anti-MIP-1
and anti-MCP-1 antibodies resulted in decreased levels of
mRNA for chemokine and cytokine to half the level in control eyes
(Figs. 5A
5B)
. The level of mRNA for RANTES remained unchanged in the
eye and periphery but decreased in the spinal cord in
anti-RANTEStreated animals. In the spleen and lymph nodes we did not
detect any marked reduction in the mRNA chemokine expression compared
with control untreated animals (Fig. 5B)
.
|
transcripts was observed in the spinal
cords of rats treated with anti-MCP-1 or MIP-1
antibodies,
respectively. To test the possibility that the administration of antibody may affect the activation of MBP-specific T cells we measured the proliferative activities against MBP of T cells obtained from draining lymph nodes or spleens. Spleen T cells showed proliferation in response to MBP to be half that in untreated rats; however, proliferative responses of lymph node cells were not altered (Fig. 5C) .
| Discussion |
|---|
|
|
|---|
,
CCL4/MIP-1ß, and CCL5/RANTESthat act toward T cells and monocytes
were upregulated simultaneously before onset of AU, and their
expression correlated with the intensity of inflammation in the eye and
CNS. The early expression of those chemokines in both organs provides a
mechanism for the later influx of macrophages and T cells. The
expression of CC chemokines involved in Th1 cell type attraction
correlated with the expression of their receptors (CCR5 and -1) in the
eyes during the course of AU, which suggests a role for these
chemokines in the pathogenicity of uveitis. In particular,
CCL4/MIP-1ß and CCL2/MCP-1 seem to play an important role in the
recruitment of inflammatory cells into the eye and CNS. Administration
of antibodies delayed onset and suppressed the development of disease.
Anti-MCP-1, but not anti-MIP-1
treatment decreased clinical severity
of EAE. However, that the anti-chemokine treatment did not completely
suppress clinical disease, but delayed onset or reduced severity,
suggests that not one, but many chemokines together promote cell
infiltration of the inflammatory site. We also do not exclude the
possibility that higher doses of antibodies may be required to
completely block those chemokines.
We do not directly know where the neutralization of endogenous
chemokines, such as CCL2/MCP-1 or CCL4/MIP-1ß, occurred, in the
inflamed tissue (eye or CNS) or in the periphery. Our data suggest that
the inhibition of their activity starts in the periphery and occurrs in
the target organs. The treatment probably affected the priming step
during antigenic stimulation, which in consequence influenced the
levels of Th1-type cytokine expression and MBP-specific responses.
Thus, it is possible that the subsequent accumulation of leukocytes in
the eye was reduced. Some chemokines trigger intravascular
adhesion.19
CCL3/MIP-1
and CCL4/MIP-1ß have been
shown to be potent chemoattractants for macrophages and T lymphocytes,
but their effect on lymphocyte differs. CCL4/MIP-1ß selectively
attracts and promotes adhesion of CD4+ T cells,
whereas CCL3/MIP-1
is more effective in the attraction and adhesion
of CD8+ T cells.20
21
Because
CD4+ T cells mediate EAE/AU, the CCCL4/MIP-1ß
antibody neutralization was more effective in suppression of clinical
disease than anti-MIP-1
treatment. CCL2/MCP-1 has been reported as a
major attractant for CD4+ T cells of the
activated-memory phenotype.22
It attracts both Th1 and
Th2, whereas CCL3/MIP-1
, CCL4/MIP-1ß, and CCL5/RANTES attract only
Th1.4
CCR5 is a major receptor for CCL3/MIP-1
,
CCL4/MIP-1ß, and CCL5/RANTES and therefore is considered to be a
Th1-associated marker.23
24
25
26
CCR2 is a major receptor for
CCL2/MCP-1.27
28
CCR2 and -5 were present in high levels
in infiltrating lymphocytes, which is in agreement with the presence of
their ligands.
The relationship between the production of chemokines in the CNS and
development of EAE has been demonstrated by several
investigators29
30
31
32
33
34
; however, there is limited information
on the role of chemokines in autoimmune eye inflammation. Our analysis
of chemokine expression revealed differences in the level of expression
between the target organs in EAE/AU in Lewis rats, although cells from
both organs expressed a similar chemokine profile, representing
CCL2/MCP-1, CCL3/MIP-1
, CCL4/MIP-1ß, and CCL5/RANTES. These
chemokines can be produced by a variety of different cells, but T cells
are a rich source of chemokines during a Th1 response, and those
T-cellsecreted chemokines seem to play an important role in the
regulation of the immune response. This suggests that the Th1 response
is a principal effector mechanism in EAE/AU. Kuchroo et
al.29
reported that encephalitogenic T cells were the
source of CCL5/RANTES, CCL3/MIP-1
, and CCL4/MIP-1ß.T cells also
can be the initial source of CCL2/MCP-1 in the EAE rat.35
We showed that the cells found in the eye during inflammation also
expressed all those chemokines. In a recent study, CCL3/MIP-1
and
CCL2/MCP-1 have been shown to play a role in the immunopathogenesis of
experimental autoimmune neuritis in Lewis rats, in which the
inflammatory infiltrates of the sciatic nerve consisted of T
lymphocytes and macrophages.36
Our results are also in agreement with findings in patients with AU, which show that IL-8, IP-10, MCP-1, RANTES, and MIP-1ß were significantly increased in the aqueous humor and correlated with the clinical severity of the disease.7 37 38 The investigators suggested that these chemoattractant cytokines play a critical role in leukocyte recruitment in acute AU.7 For example, RANTES has the potential to influence the migration of memory T cells and monocytes across the bloodaqueous barrier during inflammatory eye disease.39 40 41 42 43 RANTES also appears to play a role in the pathogenesis of relapsingremitting multiple sclerosis (RR-MS), enhancing the inflammatory response within the nervous system. RANTES production is increased in relapse and remission compared with levels in control subjects.44 In our studies, the RANTES level has been elevated but anti-RANTES treatment was not effective in suppression of acute AU. Nevertheless, its role in experimental uveitis should be investigated further. In contrast, anti-RANTES antibody treatment of MBP-immunized rats with recurrent AU had an effect on clinical disease severity, suggesting that RANTES plays a modulatory role in Th1-type selective migration during recurrent disease (Adamus et al. manuscript submitted).
The expression of chemokine receptors in the human eye has not been
determined. Moreover, there is limited information about the receptors
in experimental models of uveitis. Recently, the roles of a murine IL-8
receptor homologue (mIL-8Rh, neutrophil chemokine CXCR2) and
CCL3/MIP-1
have been examined in the eyes of experimental animals in
two eye inflammation models: endotoxin-induced uveitis (EIU) and immune
complex-induced uveitis (reverse passive Arthus reaction [RPAR]
uveitis). Chemokines acting through mIL-8Rh significantly influence the
induction of neutrophil infiltration during EIU, but not during RPAR
uveitis. However, CCL3/MIP-1
is not critical for either EIU or
RPAR-induced uveitis. The differential dependence on IL-8-like
chemokines is in agreement with the two forms of uveitides having
different origins but mostly mediated by neutrophils.45
CXCL8/IL-8 mediates neutrophil infiltration, whereas CCL2/MCP-1
mediates mononuclear cell infiltration and protein leakage in
lipopolysaccharide (LPS)-induced uveitis in rabbits.46
In
another study, the investigators showed that a CXC chemokine, GRO, and
IL-8 act in concert to mediate neutrophil infiltration in the same
LPS-induced uveitis model.47
Our studies showed for the
first time the expression of CC chemokine receptors in the iris, which
correlated with the expression of their ligands during the course of
AU.
Chemokine expression in AU provides important information regarding the pathogenesis of uveitis. The further evaluation of their roles in the initiation and regulation of disease activity may lead to the development of new therapies in human uveitis.
| Footnotes |
|---|
Supported by Grant EY12477 from the National Institutes of Health (GA).
Submitted for publication February 13, 2001; revised May 29 and July 13, 2001; accepted July 20, 2001.
Commercial relationships policy: N.
The publication costs of this article were defrayed in part by page
charge payment. This article must therefore be marked
"advertisement" in accordance with 18 U.S.C.
1734
solely to indicate this fact.
Corresponding author: Grazyna Adamus, Neurologic Sciences Institute, Oregon Health & Science University, West Campus, Building 1, 505 NW 185th Avenue, Beaverton, OR 97006. adamusg{at}ohsu.edu
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
S. Joly, M. Samardzija, A. Wenzel, M. Thiersch, and C. Grimm Nonessential Role of {beta}3 and {beta}5 Integrin Subunits for Efficient Clearance of Cellular Debris after Light-Induced Photoreceptor Degeneration Invest. Ophthalmol. Vis. Sci., March 1, 2009; 50(3): 1423 - 1432. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Bitko, A. Musiyenko, and S. Barik Viral Infection of the Lungs through the Eye J. Virol., January 15, 2007; 81(2): 783 - 790. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Adamus, G. G. Burrows, A. A. Vandenbark, and H. Offner Treatment of Autoimmune Anterior Uveitis with Recombinant TCR Ligands. Invest. Ophthalmol. Vis. Sci., June 1, 2006; 47(6): 2555 - 2561. [Abstract] [Full Text] [PDF] |
||||
![]() |
H Takase, S Sugita, C Taguchi, Y Imai, and M Mochizuki Capacity of ocular infiltrating T helper type 1 cells of patients with non-infectious uveitis to produce chemokines Br. J. Ophthalmol., June 1, 2006; 90(6): 765 - 768. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Gatti, V. Rivero, R. D. Motrich, and M. Maccioni Prostate epithelial cells can act as early sensors of infection by up-regulating TLR4 expression and proinflammatory mediators upon LPS stimulation J. Leukoc. Biol., May 1, 2006; 79(5): 989 - 998. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Hashida, N. Ohguro, K. Nakai, M. Kobashi-Hashida, S.-i. Hashimoto, K. Matsushima, and Y. Tano Microarray Analysis of Cytokine and Chemokine Gene Expression after Prednisolone Treatment in Murine Experimental Autoimmune Uveoretinitis Invest. Ophthalmol. Vis. Sci., November 1, 2005; 46(11): 4224 - 4234. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-H. Yang, I-M. Fang, C.-P. Lin, C.-M. Yang, and M.-S. Chen Effects of the NF-{kappa}B Inhibitor Pyrrolidine Dithiocarbamate on Experimentally Induced Autoimmune Anterior Uveitis Invest. Ophthalmol. Vis. Sci., April 1, 2005; 46(4): 1339 - 1347. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Curnow, K. Wloka, J. M. Faint, N. Amft, C. M. G. Cheung, V. Savant, J. Lord, A. N. Akbar, C. D. Buckley, P. I. Murray, et al. Topical Glucocorticoid Therapy Directly Induces Up-Regulation of Functional CXCR4 on Primed T Lymphocytes in the Aqueous Humor of Patients with Uveitis J. Immunol., June 1, 2004; 172(11): 7154 - 7161. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.-H. Sonoda, Y. Sasa, H. Qiao, C. Tsutsumi, T. Hisatomi, S. Komiyama, T. Kubota, T. Sakamoto, Y.-I. Kawano, and T. Ishibashi Immunoregulatory Role of Ocular Macrophages: The Macrophages Produce RANTES to Suppress Experimental Autoimmune Uveitis J. Immunol., September 1, 2003; 171(5): 2652 - 2659. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Momma, C. N. Nagineni, M. S. Chin, K. Srinivasan, B. Detrick, and J. J. Hooks Differential Expression of Chemokines by Human Retinal Pigment Epithelial Cells Infected with Cytomegalovirus Invest. Ophthalmol. Vis. Sci., May 1, 2003; 44(5): 2026 - 2033. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. Silverman, D. O. Zamora, Y. Pan, P. V. Texeira, S.-H. Baek, S. R. Planck, and J. T. Rosenbaum Constitutive and Inflammatory Mediator-Regulated Fractalkine Expression in Human Ocular Tissues and Cultured Cells Invest. Ophthalmol. Vis. Sci., April 1, 2003; 44(4): 1608 - 1615. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Gaupp, D. Pitt, W. A. Kuziel, B. Cannella, and C. S. Raine Experimental Autoimmune Encephalomyelitis (EAE) in CCR2-/- Mice: Susceptibility in Multiple Strains Am. J. Pathol., January 1, 2003; 162(1): 139 - 150. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. F. Foxman, M. Zhang, S. D. Hurst, T. Muchamuel, D. Shen, E. F. Wawrousek, C.-C. Chan, and I. Gery Inflammatory Mediators in Uveitis: Differential Induction of Cytokines and Chemokines in Th1- Versus Th2-Mediated Ocular Inflammation J. Immunol., March 1, 2002; 168(5): 2483 - 2492. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |